Trial Profile
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Dec 2021 Results of exploratory analysis assessing Watch device for sleep assessment published in the Journal of Sleep Research
- 03 Feb 2020 Results published in the Merck & Co Media Release.
- 03 Feb 2020 According to an Merck & Co media release, findings from this study were recently published online in Alzheimer's & Dementia: Journal of the Alzheimer's Association.